25 XP   0   0   10

Allogene Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Allogene together

PenkeI guess you are interested in Allogene Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Allogene Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Allogene Therapeutics Inc

I send you an email if I find something interesting about Allogene Therapeutics Inc.

Quick analysis of Allogene (30 sec.)










What can you expect buying and holding a share of Allogene? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.03
Expected worth in 1 year
$2.12
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.91
Return On Investment
-26.3%

For what price can you sell your share?

Current Price per Share
$3.46
Expected price per share
$2.23 - $5.775
How sure are you?
50%

1. Valuation of Allogene (5 min.)




Live pricePrice per Share (EOD)

$3.46

Intrinsic Value Per Share

$-17.26 - $-20.21

Total Value Per Share

$-14.23 - $-17.18

2. Growth of Allogene (5 min.)




Is Allogene growing?

Current yearPrevious yearGrowGrow %
How rich?$512.2m$765.7m-$188.1m-32.6%

How much money is Allogene making?

Current yearPrevious yearGrowGrow %
Making money-$80.8m-$82.4m$1.5m1.9%
Net Profit Margin-229,354.7%-145,865.6%--

How much money comes from the company's main activities?

3. Financial Health of Allogene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#107 / 1016

Most Revenue
#663 / 1016

Most Profit
#951 / 1016

Most Efficient
#1009 / 1016

What can you expect buying and holding a share of Allogene? (5 min.)

Welcome investor! Allogene's management wants to use your money to grow the business. In return you get a share of Allogene.

What can you expect buying and holding a share of Allogene?

First you should know what it really means to hold a share of Allogene. And how you can make/lose money.

Speculation

The Price per Share of Allogene is $3.46. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Allogene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Allogene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.03. Based on the TTM, the Book Value Change Per Share is $-0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.37 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Allogene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.51-14.7%-0.48-13.8%-0.49-14.2%-0.40-11.5%-0.37-10.6%
Usd Book Value Change Per Share-0.42-12.1%-0.23-6.6%-0.37-10.7%-0.06-1.6%0.133.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.42-12.1%-0.23-6.6%-0.37-10.7%-0.06-1.6%0.133.6%
Usd Price Per Share3.21-4.07-9.40-19.50-17.38-
Price to Earnings Ratio-1.58--2.14--4.89--15.13--14.16-
Price-to-Total Gains Ratio-7.66--1.26--26.29--69.10--65.57-
Price to Book Ratio1.06-1.18-2.07-4.00-3.60-
Price-to-Total Gains Ratio-7.66--1.26--26.29--69.10--65.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.46
Number of shares289
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.23-0.06
Usd Total Gains Per Share-0.23-0.06
Gains per Quarter (289 shares)-65.65-16.32
Gains per Year (289 shares)-262.59-65.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-263-2730-65-75
20-525-5360-131-140
30-788-7990-196-205
40-1050-10620-261-270
50-1313-13250-326-335
60-1576-15880-392-400
70-1838-18510-457-465
80-2101-21140-522-530
90-2363-23770-587-595
100-2626-26400-653-660

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.024.00.00.0%0.024.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%6.018.00.025.0%6.018.00.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%6.018.00.025.0%6.018.00.025.0%

Fundamentals of Allogene

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 00:11:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Allogene Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Allogene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • A Net Profit Margin of -408,466.7% means that $-4,084.67 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allogene Therapeutics Inc:

  • The MRQ is -408,466.7%. The company is making a huge loss. -2
  • The TTM is -229,354.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-408,466.7%TTM-229,354.7%-179,111.9%
TTM-229,354.7%YOY-145,865.6%-83,489.2%
TTM-229,354.7%5Y-98,427.4%-130,927.3%
5Y-98,427.4%10Y-82,022.9%-16,404.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-408,466.7%-197.2%-408,269.5%
TTM-229,354.7%-210.4%-229,144.3%
YOY-145,865.6%-279.3%-145,586.3%
5Y-98,427.4%-436.8%-97,990.6%
10Y-82,022.9%-599.3%-81,423.6%
1.1.2. Return on Assets

Shows how efficient Allogene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • -13.3% Return on Assets means that Allogene generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allogene Therapeutics Inc:

  • The MRQ is -13.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.3%TTM-11.3%-2.0%
TTM-11.3%YOY-9.2%-2.1%
TTM-11.3%5Y-7.7%-3.6%
5Y-7.7%10Y-9.0%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.3%-13.6%+0.3%
TTM-11.3%-12.9%+1.6%
YOY-9.2%-11.9%+2.7%
5Y-7.7%-14.2%+6.5%
10Y-9.0%-16.2%+7.2%
1.1.3. Return on Equity

Shows how efficient Allogene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • -16.7% Return on Equity means Allogene generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allogene Therapeutics Inc:

  • The MRQ is -16.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.7%TTM-14.1%-2.6%
TTM-14.1%YOY-10.9%-3.2%
TTM-14.1%5Y-9.1%-5.0%
5Y-9.1%10Y-9.7%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.7%-17.0%+0.3%
TTM-14.1%-16.1%+2.0%
YOY-10.9%-15.4%+4.5%
5Y-9.1%-20.0%+10.9%
10Y-9.7%-21.1%+11.4%

1.2. Operating Efficiency of Allogene Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Allogene is operating .

  • Measures how much profit Allogene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • An Operating Margin of -342,519.0% means the company generated $-3,425.19  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allogene Therapeutics Inc:

  • The MRQ is -342,519.0%. The company is operating very inefficient. -2
  • The TTM is -217,307.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-342,519.0%TTM-217,307.9%-125,211.2%
TTM-217,307.9%YOY-141,740.3%-75,567.5%
TTM-217,307.9%5Y-95,471.2%-121,836.6%
5Y-95,471.2%10Y-79,559.4%-15,911.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-342,519.0%-286.1%-342,232.9%
TTM-217,307.9%-224.4%-217,083.5%
YOY-141,740.3%-288.4%-141,451.9%
5Y-95,471.2%-475.2%-94,996.0%
10Y-79,559.4%-624.7%-78,934.7%
1.2.2. Operating Ratio

Measures how efficient Allogene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3,423.10 means that the operating costs are $3,423.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 3,423.095. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2,216.619. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3,423.095TTM2,216.619+1,206.477
TTM2,216.619YOY1,539.190+677.429
TTM2,216.6195Y983.819+1,232.800
5Y983.81910Y819.849+163.970
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3,423.0952.997+3,420.098
TTM2,216.6193.247+2,213.372
YOY1,539.1903.766+1,535.424
5Y983.8195.675+978.144
10Y819.8497.857+811.992

1.3. Liquidity of Allogene Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Allogene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.38 means the company has $12.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 12.382. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.691. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.382TTM10.691+1.691
TTM10.691YOY11.376-0.685
TTM10.6915Y13.518-2.827
5Y13.51810Y13.231+0.287
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.3823.930+8.452
TTM10.6914.251+6.440
YOY11.3765.436+5.940
5Y13.5186.045+7.473
10Y13.2316.363+6.868
1.3.2. Quick Ratio

Measures if Allogene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • A Quick Ratio of 21.96 means the company can pay off $21.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 21.960. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.700. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.960TTM18.700+3.260
TTM18.700YOY20.615-1.916
TTM18.7005Y23.519-4.820
5Y23.51910Y22.080+1.440
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.9603.629+18.331
TTM18.7004.065+14.635
YOY20.6155.397+15.218
5Y23.5195.993+17.526
10Y22.0806.277+15.803

1.4. Solvency of Allogene Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Allogene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Allogene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20 means that Allogene assets are financed with 20.3% credit (debt) and the remaining percentage (100% - 20.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 0.203. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.196. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.203TTM0.196+0.007
TTM0.196YOY0.155+0.041
TTM0.1965Y0.132+0.064
5Y0.13210Y0.179-0.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2030.332-0.129
TTM0.1960.334-0.138
YOY0.1550.268-0.113
5Y0.1320.366-0.234
10Y0.1790.390-0.211
1.4.2. Debt to Equity Ratio

Measures if Allogene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 25.5% means that company has $0.25 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 0.255. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.244. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.255TTM0.244+0.011
TTM0.244YOY0.184+0.060
TTM0.2445Y0.155+0.089
5Y0.15510Y0.136+0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2550.381-0.126
TTM0.2440.390-0.146
YOY0.1840.334-0.150
5Y0.1550.434-0.279
10Y0.1360.466-0.330

2. Market Valuation of Allogene Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Allogene generates.

  • Above 15 is considered overpriced but always compare Allogene to the Biotechnology industry mean.
  • A PE ratio of -1.58 means the investor is paying $-1.58 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allogene Therapeutics Inc:

  • The EOD is -1.705. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.582. Based on the earnings, the company is expensive. -2
  • The TTM is -2.144. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.705MRQ-1.582-0.123
MRQ-1.582TTM-2.144+0.562
TTM-2.144YOY-4.890+2.746
TTM-2.1445Y-15.126+12.982
5Y-15.12610Y-14.160-0.966
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.705-2.315+0.610
MRQ-1.582-2.560+0.978
TTM-2.144-2.664+0.520
YOY-4.890-4.122-0.768
5Y-15.126-6.258-8.868
10Y-14.160-6.108-8.052
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Allogene Therapeutics Inc:

  • The EOD is -2.714. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.518. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.849. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.714MRQ-2.518-0.196
MRQ-2.518TTM-2.849+0.331
TTM-2.849YOY-7.543+4.693
TTM-2.8495Y-17.647+14.798
5Y-17.64710Y-16.786-0.861
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.714-3.067+0.353
MRQ-2.518-3.251+0.733
TTM-2.849-3.545+0.696
YOY-7.543-5.595-1.948
5Y-17.647-8.315-9.332
10Y-16.786-8.708-8.078
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Allogene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.06 means the investor is paying $1.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Allogene Therapeutics Inc:

  • The EOD is 1.142. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.060. Based on the equity, the company is underpriced. +1
  • The TTM is 1.185. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.142MRQ1.060+0.083
MRQ1.060TTM1.185-0.125
TTM1.185YOY2.068-0.883
TTM1.1855Y3.997-2.813
5Y3.99710Y3.601+0.396
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1421.905-0.763
MRQ1.0602.111-1.051
TTM1.1852.095-0.910
YOY2.0682.836-0.768
5Y3.9973.443+0.554
10Y3.6013.794-0.193
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Allogene Therapeutics Inc.

3.1. Institutions holding Allogene Therapeutics Inc

Institutions are holding 73.78% of the shares of Allogene Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc14.92770.006225241499975680.388
2023-12-31TPG GP A, LLC11.06870.9691871630600
2023-12-31BlackRock Inc5.9150.000810001804110782412.4559
2023-12-31Vanguard Group Inc5.34080.00069030825-1556979-14.7054
2023-12-31JPMorgan Chase & Co4.08460.00216906761-4121-0.0596
2023-12-31Goldman Sachs Group Inc3.94720.001966744285266472374.0509
2023-12-31PRIMECAP Management Company3.12370.01345281886-2500-0.0473
2023-09-30Citadel Advisors Llc2.4340.00284115630-624711-13.1786
2023-12-31Woodline Partners LP1.52430.092577500-2736415-51.4953
2023-12-31State Street Corporation1.43550.00042427284-5775317-70.4084
2023-12-31T. Rowe Price Associates, Inc.1.40250.0012371472-35875-1.4902
2023-12-31Geode Capital Management, LLC1.3810.0008233519526384212.7377
2023-12-31Two Sigma Investments LLC1.36880.01712314541101432078.0114
2023-12-31Wildcat Capital Management, LLC1.13592.132192078700
2023-12-31Millennium Management LLC1.13490.0027191901417946161442.6406
2023-12-31Vida Ventures Advisors, LLC1.06346.8717179816300
2023-12-31Morgan Stanley - Brokerage Accounts0.98630.0005166782628610820.7067
2023-12-31Dimensional Fund Advisors, Inc.0.90790.00141535245-303111-16.4882
2023-12-31Two Sigma Advisers, LLC0.75560.0096127770030050030.7511
2023-12-31Northern Trust Corp0.59990.0006101434515381817.8749
Total 64.537710.1246109128211-753961-0.7%

3.2. Funds holding Allogene Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF3.87150.38756546361825601.2773
2024-02-29Fidelity Growth Compy Commingled Pl O2.49720.02644222588359610.8589
2024-02-29Fidelity Select Health Care2.36560.2481400000000
2024-02-29Vanguard Total Stock Mkt Idx Inv2.0310.00113434239-442200-11.4074
2023-12-31Vanguard Capital Opportunity Inv1.99770.0516337787900
2024-02-29Fidelity Advisor Health Care I1.65590.27632800000-83755-2.9044
2024-03-28iShares Russell 2000 ETF1.38030.0159233401011250.0482
2024-02-29Fidelity Select Biotechnology1.34710.2275227788800
2024-02-29Fidelity Growth Company Fund1.22660.01712074057266001.2992
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.090.00891843183-32425-1.7288
2023-12-31PRIMECAP Odyssey Aggressive Growth1.07180.08091812271-2000-0.1102
2024-02-29JPMorgan Small Cap Growth A0.9880.20261670565-2097-0.1254
2024-01-31Fidelity Small Cap Growth0.93240.09681576680-1903-0.1206
2024-01-31Fidelity Series Small Cap Opps0.89460.1029151270000
2024-02-29Vanguard Small Cap Index0.83430.00491410725127890.9148
2023-12-31T. Rowe Price Health Sciences0.78110.02881320696-27444-2.0357
2024-02-29Fidelity Growth Company K60.77680.0351131349570280.5379
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD0.63060.67951066219-16132-1.4905
2024-01-31Fidelity Small Cap Index0.56080.013594827298551.0502
2024-03-28iShares Russell 2000 Value ETF0.52240.0315883264-560-0.0634
Total 27.45572.536946425092-432598-0.9%

3.3. Insider Transactions

Insiders are holding 22.44% of the shares of Allogene Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-30Geoffrey M ParkerBUY1903.6
2023-12-18Deborah M MessemerSELL186402.7
2023-08-07Stephen MayoSELL100004.29

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Allogene Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.419-0.227-46%-0.370-12%-0.056-87%0.126-432%
Book Value Per Share--3.0293.416-11%4.529-33%4.704-36%4.153-27%
Current Ratio--12.38210.691+16%11.376+9%13.518-8%13.231-6%
Debt To Asset Ratio--0.2030.196+4%0.155+31%0.132+54%0.179+14%
Debt To Equity Ratio--0.2550.244+5%0.184+39%0.155+65%0.136+88%
Dividend Per Share----0%-0%-0%-0%
Eps---0.507-0.479-6%-0.492-3%-0.399-21%-0.368-27%
Free Cash Flow Per Share---0.319-0.354+11%-0.334+5%-0.308-3%-0.268-16%
Free Cash Flow To Equity Per Share---0.318-0.212-33%-0.329+4%-0.070-78%0.187-270%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---20.210--------
Intrinsic Value_10Y_min---17.256--------
Intrinsic Value_1Y_max---1.427--------
Intrinsic Value_1Y_min---1.401--------
Intrinsic Value_3Y_max---4.743--------
Intrinsic Value_3Y_min---4.519--------
Intrinsic Value_5Y_max---8.609--------
Intrinsic Value_5Y_min---7.951--------
Market Cap585058320.000+7%542785320.000688627170.000-21%1589464800.000-66%3298097187.000-84%2938149637.500-82%
Net Profit Margin---4084.667-2293.547-44%-1458.656-64%-984.274-76%-820.229-80%
Operating Margin---3425.190-2173.079-37%-1417.403-59%-954.712-72%-795.594-77%
Operating Ratio--3423.0952216.619+54%1539.190+122%983.819+248%819.849+318%
Pb Ratio1.142+7%1.0601.185-11%2.068-49%3.997-73%3.601-71%
Pe Ratio-1.705-8%-1.582-2.144+36%-4.890+209%-15.126+856%-14.160+795%
Price Per Share3.460+7%3.2104.073-21%9.400-66%19.505-84%17.376-82%
Price To Free Cash Flow Ratio-2.714-8%-2.518-2.849+13%-7.543+200%-17.647+601%-16.786+567%
Price To Total Gains Ratio-8.255-8%-7.659-1.262-84%-26.294+243%-69.105+802%-65.565+756%
Quick Ratio--21.96018.700+17%20.615+7%23.519-7%22.080-1%
Return On Assets---0.133-0.113-15%-0.092-31%-0.077-42%-0.090-33%
Return On Equity---0.167-0.141-16%-0.109-35%-0.091-46%-0.097-42%
Total Gains Per Share---0.419-0.227-46%-0.370-12%-0.056-87%0.126-432%
Usd Book Value--512233000.000577625750.000-11%765752500.000-33%795367000.000-36%702303541.667-27%
Usd Book Value Change Per Share---0.419-0.227-46%-0.370-12%-0.056-87%0.126-432%
Usd Book Value Per Share--3.0293.416-11%4.529-33%4.704-36%4.153-27%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.507-0.479-6%-0.492-3%-0.399-21%-0.368-27%
Usd Free Cash Flow---53888000.000-59812250.000+11%-56427500.000+5%-52020450.000-3%-45345666.667-16%
Usd Free Cash Flow Per Share---0.319-0.354+11%-0.334+5%-0.308-3%-0.268-16%
Usd Free Cash Flow To Equity Per Share---0.318-0.212-33%-0.329+4%-0.070-78%0.187-270%
Usd Market Cap585058320.000+7%542785320.000688627170.000-21%1589464800.000-66%3298097187.000-84%2938149637.500-82%
Usd Price Per Share3.460+7%3.2104.073-21%9.400-66%19.505-84%17.376-82%
Usd Profit---85778000.000-80855000.000-6%-82411500.000-4%-67244300.000-22%-64849625.000-24%
Usd Revenue--21000.00040000.000-48%60750.000-65%1944600.000-99%1620500.000-99%
Usd Total Gains Per Share---0.419-0.227-46%-0.370-12%-0.056-87%0.126-432%
 EOD+5 -3MRQTTM+7 -26YOY+10 -235Y+3 -3010Y+3 -30

4.2. Fundamental Score

Let's check the fundamental score of Allogene Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.705
Price to Book Ratio (EOD)Between0-11.142
Net Profit Margin (MRQ)Greater than0-4,084.667
Operating Margin (MRQ)Greater than0-3,425.190
Quick Ratio (MRQ)Greater than121.960
Current Ratio (MRQ)Greater than112.382
Debt to Asset Ratio (MRQ)Less than10.203
Debt to Equity Ratio (MRQ)Less than10.255
Return on Equity (MRQ)Greater than0.15-0.167
Return on Assets (MRQ)Greater than0.05-0.133
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Allogene Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.535
Ma 20Greater thanMa 504.030
Ma 50Greater thanMa 1004.496
Ma 100Greater thanMa 2003.768
OpenGreater thanClose3.520
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  -3,261-401-3,662-87-3,749220-3,5293,55021



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets642,837
Total Liabilities130,604
Total Stockholder Equity512,233
 As reported
Total Liabilities 130,604
Total Stockholder Equity+ 512,233
Total Assets = 642,837

Assets

Total Assets642,837
Total Current Assets459,115
Long-term Assets183,722
Total Current Assets
Cash And Cash Equivalents 83,155
Short-term Investments 365,542
Other Current Assets 10,418
Total Current Assets  (as reported)459,115
Total Current Assets  (calculated)459,115
+/-0
Long-term Assets
Property Plant Equipment 163,181
Long Term Investments 3,645
Long-term Assets Other 16,896
Long-term Assets  (as reported)183,722
Long-term Assets  (calculated)183,722
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities37,079
Long-term Liabilities93,525
Total Stockholder Equity512,233
Total Current Liabilities
Short-term Debt 6,775
Accounts payable 5,897
Other Current Liabilities 24,321
Total Current Liabilities  (as reported)37,079
Total Current Liabilities  (calculated)36,993
+/- 86
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt88,346
Long-term Liabilities Other 5,179
Long-term Liabilities  (as reported)93,525
Long-term Liabilities  (calculated)93,525
+/-0
Total Stockholder Equity
Common Stock169
Retained Earnings -1,562,233
Accumulated Other Comprehensive Income -955
Other Stockholders Equity 2,075,252
Total Stockholder Equity (as reported)512,233
Total Stockholder Equity (calculated)512,233
+/-0
Other
Capital Stock169
Cash and Short Term Investments 448,697
Common Stock Shares Outstanding 168,336
Current Deferred Revenue86
Liabilities and Stockholders Equity 642,837
Net Debt 11,966
Net Invested Capital 512,233
Net Working Capital 422,036
Property Plant and Equipment Gross 214,265
Short Long Term Debt Total 95,121



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
0
148,845
298,845
435,235
773,855
749,369
733,997
695,544
717,802
688,523
1,258,544
1,222,500
1,227,829
1,179,044
1,126,724
1,079,246
1,038,634
964,632
947,644
887,572
817,079
746,871
770,971
712,326
642,837
642,837712,326770,971746,871817,079887,572947,644964,6321,038,6341,079,2461,126,7241,179,0441,227,8291,222,5001,258,544688,523717,802695,544733,997749,369773,855435,235298,845148,8450
   > Total Current Assets 
0
144,264
294,264
247,353
467,982
476,627
511,542
509,757
544,576
504,414
909,577
854,058
845,130
716,061
602,171
502,858
809,481
469,744
513,028
569,061
528,824
514,012
502,101
473,454
459,115
459,115473,454502,101514,012528,824569,061513,028469,744809,481502,858602,171716,061845,130854,058909,577504,414544,576509,757511,542476,627467,982247,353294,264144,2640
       Cash And Cash Equivalents 
0
143,927
293,927
83,141
721,350
92,748
650,193
160,990
588,855
135,897
280,379
1,049,015
1,032,118
236,865
223,503
190,021
809,481
84,514
96,041
74,357
576,471
514,012
154,758
69,246
83,155
83,15569,246154,758514,012576,47174,35796,04184,514809,481190,021223,503236,8651,032,1181,049,015280,379135,897588,855160,990650,19392,748721,35083,141293,927143,9270
       Short-term Investments 
0
0
0
161,080
366,952
373,392
389,840
340,254
355,407
357,026
619,271
682,886
644,559
462,716
364,204
293,464
283,988
364,536
394,451
477,872
455,416
361,293
337,204
396,259
365,542
365,542396,259337,204361,293455,416477,872394,451364,536283,988293,464364,204462,716644,559682,886619,271357,026355,407340,254389,840373,392366,952161,080000
       Net Receivables 
0
0
0
0
3,108
3,391
3,285
2,337
2,403
200
800
2,274
5,169
6,275
4,300
6,160
5,815
9,042
11,900
5,800
3,300
2,200
1,100
1,600
0
01,6001,1002,2003,3005,80011,9009,0425,8156,1604,3006,2755,1692,2748002002,4032,3373,2853,3913,1080000
       Other Current Assets 
0
0
337
3,132
5,490
7,096
5,833
6,176
11,640
11,491
9,927
13,036
17,220
16,480
14,464
19,373
14,021
20,694
22,536
16,832
11,504
10,241
10,139
7,949
10,418
10,4187,94910,13910,24111,50416,83222,53620,69414,02119,37314,46416,48017,22013,0369,92711,49111,6406,1765,8337,0965,4903,13233700
   > Long-term Assets 
0
0
4,581
187,882
305,873
272,742
222,455
185,787
173,226
184,109
348,967
368,442
382,699
462,983
524,553
576,388
229,153
494,888
434,616
318,511
288,255
232,859
268,870
238,872
183,722
183,722238,872268,870232,859288,255318,511434,616494,888229,153576,388524,553462,983382,699368,442348,967184,109173,226185,787222,455272,742305,873187,8824,58100
       Property Plant Equipment 
0
3,526
3,526
29,689
41,610
52,820
67,697
77,380
100,944
110,185
127,037
144,210
160,135
163,335
164,933
164,647
181,020
177,257
204,053
199,687
196,431
191,813
186,700
181,469
163,181
163,181181,469186,700191,813196,431199,687204,053177,257181,020164,647164,933163,335160,135144,210127,037110,185100,94477,38067,69752,82041,61029,6893,5263,5260
       Long Term Investments 
0
0
0
154,045
261,966
214,588
147,769
100,702
63,214
64,950
215,471
212,509
204,208
283,924
344,342
396,132
352,179
298,297
211,333
99,154
71,968
53,912
62,496
37,535
3,645
3,64537,53562,49653,91271,96899,154211,333298,297352,179396,132344,342283,924204,208212,509215,47164,95063,214100,702147,769214,588261,966154,045000
       Intangible Assets 
0
1,055
1,055
904
754
603
452
301
151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001513014526037549041,0551,0550
       Other Assets 
0
0
1,055
3,244
1,543
4,731
6,537
7,404
8,917
8,974
6,459
265,789
263,859
15,724
15,278
15,609
16,107
16,334
16,230
16,670
16,856
0
16,674
0
0
0016,674016,85616,67016,23016,33416,10715,60915,27815,724263,859265,7896,4598,9748,9177,4046,5374,7311,5433,2441,05500
> Total Liabilities 
2
17,233
17,233
603,678
70,691
68,141
78,362
75,828
88,779
82,004
95,125
103,769
148,212
109,265
102,912
109,304
122,228
109,402
145,695
147,611
151,209
154,609
148,065
129,224
130,604
130,604129,224148,065154,609151,209147,611145,695109,402122,228109,304102,912109,265148,212103,76995,12582,00488,77975,82878,36268,14170,691603,67817,23317,2332
   > Total Current Liabilities 
2
14,745
14,745
159,477
29,459
27,265
38,000
33,354
33,079
26,818
40,895
50,130
94,320
54,849
45,998
53,490
48,174
36,877
44,909
48,872
54,518
59,585
54,721
37,636
37,079
37,07937,63654,72159,58554,51848,87244,90936,87748,17453,49045,99854,84994,32050,13040,89526,81833,07933,35438,00027,26529,459159,47714,74514,7452
       Short-term Debt 
0
0
0
139,615
0
0
0
0
0
0
0
50,846
2,974
51,625
0
0
0
0
5,344
5,831
6,002
6,189
6,381
6,578
6,775
6,7756,5786,3816,1896,0025,8315,344000051,6252,97450,8460000000139,615000
       Accounts payable 
0
1,268
1,268
3,083
12,338
12,976
23,503
8,047
9,250
7,199
9,057
10,151
10,390
14,875
11,005
11,499
10,255
8,708
9,713
11,045
13,890
14,688
10,229
6,205
5,897
5,8976,20510,22914,68813,89011,0459,7138,70810,25511,49911,00514,87510,39010,1519,0577,1999,2508,04723,50312,97612,3383,0831,2681,2680
       Other Current Liabilities 
2
3,079
13,477
3,883
17,121
14,289
14,497
25,307
23,829
19,619
31,838
39,979
41,964
39,735
34,688
41,626
37,496
27,763
29,016
31,107
33,741
38,435
37,882
24,617
24,321
24,32124,61737,88238,43533,74131,10729,01627,76337,49641,62634,68839,73541,96439,97931,83819,61923,82925,30714,49714,28917,1213,88313,4773,0792
   > Long-term Liabilities 
0
0
2,488
444,201
41,232
40,876
40,362
42,474
55,700
55,186
54,230
53,639
53,892
54,416
56,914
55,814
74,054
72,525
100,786
98,739
96,691
95,024
93,344
91,588
93,525
93,52591,58893,34495,02496,69198,739100,78672,52574,05455,81456,91454,41653,89253,63954,23055,18655,70042,47440,36240,87641,232444,2012,48800
       Warrants
0
0
0
411,052
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000411,052000
       Other Liabilities 
0
2,488
2,488
7,488
6,776
6,065
5,495
4,785
4,351
3,650
3,163
2,793
3,083
2,791
5,705
5,175
4,125
3,490
2,554
2,033
1,569
0
0
0
0
00001,5692,0332,5543,4904,1255,1755,7052,7913,0832,7933,1633,6504,3514,7855,4956,0656,7767,4882,4882,4880
       Deferred Long Term Liability 
0
0
0
2,200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,200000
> Total Stockholder Equity
-2
-2
281,612
-168,443
703,164
681,228
655,635
619,716
629,023
606,519
1,163,419
1,118,731
1,079,617
1,069,779
1,023,812
969,942
916,406
855,230
801,949
739,961
665,870
592,262
622,906
583,102
512,233
512,233583,102622,906592,262665,870739,961801,949855,230916,406969,9421,023,8121,069,7791,079,6171,118,7311,163,419606,519629,023619,716655,635681,228703,164-168,443281,612-2-2
   Retained Earnings -1,562,233-1,473,988-1,412,673-1,334,684-1,235,980-1,141,133-1,057,985-983,198-903,348-828,480-750,294-679,358-646,343-577,773-511,576-450,602-396,122-335,092-284,357-243,114-211,528-181,019-137,522-137,501-2
   Accumulated Other Comprehensive Income 
0
0
-299
-148
306
1,405
2,161
1,866
1,145
1,610
1,830
953
268
-101
-334
-398
-2,567
-9,249
-11,472
-12,958
-9,926
-5,934
-3,851
-2,411
-955
-955-2,411-3,851-5,934-9,926-12,958-11,472-9,249-2,567-398-334-1012689531,8301,6101,1451,8662,1611,405306-148-29900
   Capital Surplus 
0
0
0
12,693
914,265
922,816
937,709
952,820
1,023,876
1,055,386
1,673,026
1,695,411
1,725,552
1,749,097
1,774,298
1,798,678
1,822,179
1,847,534
1,871,262
1,893,908
0
1,932,734
2,039,263
0
0
002,039,2631,932,73401,893,9081,871,2621,847,5341,822,1791,798,6781,774,2981,749,0971,725,5521,695,4111,673,0261,055,3861,023,876952,820937,709922,816914,26512,693000
   Treasury Stock0000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue95
Cost of Revenue-0
Gross Profit9595
 
Operating Income (+$)
Gross Profit95
Operating Expense-314,587
Operating Income-314,492-314,492
 
Operating Expense (+$)
Research Development242,914
Selling General Administrative71,673
Selling And Marketing Expenses0
Operating Expense314,587314,587
 
Net Interest Income (+$)
Interest Income14,799
Interest Expense-0
Other Finance Cost-0
Net Interest Income14,799
 
Pretax Income (+$)
Operating Income-314,492
Net Interest Income14,799
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-327,265-301,719
EBIT - interestExpense = -301,247
-314,020
-327,265
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-301,247-327,265
Earnings Before Interest and Taxes (EBITDA)-287,048
 
After tax Income (+$)
Income Before Tax-327,265
Tax Provision-0
Net Income From Continuing Ops-332,855-327,265
Net Income-327,265
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses314,587
Total Other Income/Expenses Net-12,773-14,799
 

Technical Analysis of Allogene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Allogene. The general trend of Allogene is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Allogene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Allogene Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.12 < 4.63 < 5.775.

The bearish price targets are: 2.61 > 2.25 > 2.23.

Tweet this
Allogene Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Allogene Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Allogene Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Allogene Therapeutics Inc. The current macd is -0.26127581.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Allogene price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Allogene. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Allogene price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Allogene Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAllogene Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Allogene Therapeutics Inc. The current adx is 22.24.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Allogene shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Allogene Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Allogene Therapeutics Inc. The current sar is 4.11655483.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Allogene Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Allogene Therapeutics Inc. The current rsi is 29.53. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Allogene Therapeutics Inc Daily Relative Strength Index (RSI) ChartAllogene Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Allogene Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Allogene price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Allogene Therapeutics Inc Daily Stochastic Oscillator ChartAllogene Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Allogene Therapeutics Inc. The current cci is -154.22392386.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Allogene Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAllogene Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Allogene Therapeutics Inc. The current cmo is -57.02827848.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Allogene Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAllogene Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Allogene Therapeutics Inc. The current willr is -93.83886256.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Allogene Therapeutics Inc Daily Williams %R ChartAllogene Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Allogene Therapeutics Inc.

Allogene Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Allogene Therapeutics Inc. The current atr is 0.25917008.

Allogene Therapeutics Inc Daily Average True Range (ATR) ChartAllogene Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Allogene Therapeutics Inc. The current obv is 43,318,108.

Allogene Therapeutics Inc Daily On-Balance Volume (OBV) ChartAllogene Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Allogene Therapeutics Inc. The current mfi is 37.34.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Allogene Therapeutics Inc Daily Money Flow Index (MFI) ChartAllogene Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Allogene Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Allogene Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Allogene Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.535
Ma 20Greater thanMa 504.030
Ma 50Greater thanMa 1004.496
Ma 100Greater thanMa 2003.768
OpenGreater thanClose3.520
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Allogene with someone you think should read this too:
  • Are you bullish or bearish on Allogene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Allogene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Allogene Therapeutics Inc

I send you an email if I find something interesting about Allogene Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Allogene Therapeutics Inc.

Receive notifications about Allogene Therapeutics Inc in your mailbox!